15 September 2026 : Original article
Four Years of Clinical Experience With COVID-19 Outcomes in Heart Transplant Recipients
Agnieszka Kuczaj
ABCDEFG 1*, Szymon Warwas BCDEF 1, Mikołaj Tyrka BDEF 1, Błażej Skotnicki BDEF 1, Daniel Szymecki BDEF 1, Oliwia Jewuła BDEF 1, Joanna Śliwka ADEF 1, Szymon Pawlak ADEF 1, Piotr Przybyłowski ADEF 1, Tomasz Hrapkowicz ADEF 1
DOI: 10.12659/AOT.952888
Ann Transplant 2026; 31:e952888
Table 1 Clinical characteristics between COVID-19 survivors and non-survivors. Data are presented as median (IQR) or number (%).
| Clinical data | Whole population (n = 556) | Survivors (n = 538) | Deceased due to COVID-19 (n = 18) | P value |
|---|---|---|---|---|
| Age, years | 58 (44–66) | 58 (44–66) | 64.6 (60–71) | 0.009 |
| Male sex, n (%) | 424 (76.3) | 408 (75.8) | 16 (88.9) | 0.32 |
| Body mass index (kg/m) | 26.15 (23.9–29.7) | 26.15 (23.9–29.6) | 28.17 (24.2–30.4) | 0.23 |
| Obesity, n (%) | 126 (22.7) | 120 (22.3) | 6 (33.3) | 0.42 |
| Creatinine level (mg/dl) | 114 (91–146) | 112.5 (90–145) | 164 (125–179) | < 0.001 |
| Diabetes mellitus type 2, n (%) | 283 (50.9) | 269 (50) | 14 (77.8) | 0.04 |
| Arterial hypertension, n (%) | 429 (77.2) | 413 (76.8) | 16 (88.9) | 0.36 |
| Vaccinated, n (%)* | 432 (80.1) | 424 (80.8) | 8 (57.1) | 0.06 |
| Follow-up time since heart transplantation (days) | 3284 (1777–5882) | 3238 (1661–5865) | 4500 (2147–6384) | 0.64 |
| * We gathered information about the status of vaccination from 539 people: 525 survived and 14 died due to COVID-19. | ||||